OncoCyte (NASDAQ:OCX – Get Free Report) had its target price increased by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside […]
MaxCyte s (MXCT) Overweight Rating Reiterated at Stephens theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Monday morning. The brokerage issued a sell rating on the stock. Several other analysts also recently commented on the stock. Piper Sandler reduced their target price on shares of OncoCyte from $3.50 to $3.00 and set a neutral rating […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note published on Wednesday morning. The firm issued a sell rating on the stock. Several other research analysts have also recently issued reports on the company. Benchmark dropped their price target on OncoCyte from $9.00 to $5.00 and set a speculative […]
StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Friday. The firm issued a sell rating on the stock. Several other equities analysts have also weighed in on the company. Benchmark cut their target price on OncoCyte from $9.00 to $5.00 and set a speculative […]